Back
Harvard Bioscience 10K Form
Sell
21
HBIO
Harvard Bioscience
Last Price:
$0.65
Seasonality Move:
-0.31%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-05-07 | 10Q | HBIO/Harvard Bioscience Quarterly |
2023-11-07 | 10Q | HBIO/Harvard Bioscience Quarterly |
2023-08-08 | 10Q | HBIO/Harvard Bioscience Quarterly |
2023-04-26 | 10Q | HBIO/Harvard Bioscience Quarterly |
2022-11-09 | 10Q | HBIO/Harvard Bioscience Quarterly |
2022-08-04 | 10Q | HBIO/Harvard Bioscience Quarterly |
Receive HBIO News And Ratings
See the #1 stock for the next 7 days that we like better than HBIO
HBIO Financial Statistics
Sales & Book Value
Annual Sales: | $94.1M |
---|---|
Cash Flow: | $1.3M |
Price / Cash Flow: | 185.32 |
Annual Sales: | $1.44 |
Price / Book: | 0.48 |
Profitability
EPS (TTM): | -0.29000 |
---|---|
Net Income (TTM): | $-12.4M |
Gross Margin: | $54.8M |
Return on Equity: | -18.36% |
Return on Assets: | -9.44% |
Harvard Bioscience Earnings Forecast
Key Harvard Bioscience Financial Ratios
-
The Gross Profit Margin over the past 27 years for HBIO is 58.18%.
-
The Selling, General & Administrative Expenses for HBIO have been equal to 46.43% of Gross Profit Margin.
-
The Research & Development expenses have been 11.05% of Revenue.
-
The Net Earning history of HBIO is -13.18% of Total Revenues.
-
Per Share Earnings over the last 27 years have been positive in 13 years.
Harvard Bioscience Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Life Sciences Tools & Services |
Sector: | Health Care |
Current Symbol: | HBIO |
CUSIP: | 416906 |
Website: | harvardbioscience.com |
Debt
Debt-to-Equity Ratio: | 0.58 |
---|---|
Current Ratio: | 0.82 |
Quick Ratio: | 0.35 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 5.3 |
HBIO Technical Analysis vs Fundamental Analysis
Sell
21
Harvard Bioscience (HBIO)
is a Sell
Is Harvard Bioscience a Buy or a Sell?
-
Harvard Bioscience stock is rated a SellThe current Harvard Bioscience [HBIO] share price is $0.69. The Score for HBIO is 21, which is 58% below its historic median score of 50, and infers higher risk than normal.